Medicine and Dentistry
Glioblastoma
100%
Ganglioglioma
83%
Neoplasm
61%
Temozolomide
34%
Carbon 13
31%
Brain Tumor
28%
Overall Survival
23%
Malignant Neoplasm
22%
2 Hydroxyglutaric Acid
21%
Blood Brain Barrier
21%
Hazard Ratio
21%
Lactic Acid
20%
Disease
19%
Retrospective Study
15%
Surgery
15%
Nuclear Magnetic Resonance Spectroscopy
15%
Bile Acid
14%
Citric Acid Cycle
14%
Neural Stem Cell
14%
Epidermal Growth Factor Receptor
14%
Breast Cancer
14%
Nanoparticle
14%
Brain Metastasis
14%
Metastatic Carcinoma
12%
Radiation Therapy
12%
Progression Free Survival
12%
Homeostasis
12%
Clear Cell Renal Cell Carcinoma
11%
Glucose Oxidation
10%
Isocitrate Dehydrogenase
10%
Epileptic Seizure
9%
Recurrent Disease
9%
Spectroscopic Imaging
9%
Clinical Trial
8%
Pyruvic Acid
8%
Receptor
8%
Small Intestine
8%
Tumor Cell
8%
Bevacizumab
8%
Primary Tumor
8%
Targeted Therapy
8%
Carmustine
7%
Heterozygosity
7%
Thoracic Spine
7%
Pentose Phosphate Cycle
7%
Brain Metabolism
7%
Cervical Spine
7%
Anaplastic Carcinoma
7%
Nervous System Dysfunction
7%
Tertiary Care
7%
Pleomorphic Xanthoastrocytoma
7%
Tumor Necrosis Factor
7%
Neutrophilia
7%
Thromboembolism
7%
Farnesoid X Receptor
7%
Drug Distribution
7%
Trebananib
7%
Muscle Regeneration
7%
Embryonic Stem Cell
7%
Rituximab
7%
Gamma Knife Radiosurgery
7%
Tumour Heterogeneity
7%
Thrombocytopenia
7%
microRNA 146a
7%
Gene Mutation
7%
Ewing Sarcoma
7%
Gliosarcoma
7%
Fibroblast Growth Factor
7%
Socioeconomic Status
7%
Ganglionectomy
7%
Spermatozoon Maturation
7%
Aptamer
7%
Astrocyte
7%
Brain Radiation
7%
Placebo-Controlled Study
7%
Anaplastic Lymphoma Kinase
7%
Primitive Neuroectodermal Tumor
7%
Pilocytic Astrocytoma
7%
Intensity Modulated Radiation Therapy
7%
B Cell
7%
Venous Thromboembolism
7%
Radiology
7%
Antiinfective Agent
7%
Primary Central Nervous System Lymphoma
7%
Small Cell Lung Cancer
7%
Glucose Metabolism
7%
DNA Damage
7%
Rhabdomyosarcoma
7%
Lymphocyte
7%
Brainstem Glioma
7%
Extracellular Matrix
7%
Clinical Decision Making
7%
Cerebrospinal Fluid
7%
Neurologic Disease
7%
Gamma-Aminobutyric Acid
7%
Drug Megadose
6%
Arm
6%
Glutamine
6%
Stem Cell
6%
Pediatrics
5%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
50%
Astrocyte
38%
Metabolic Pathway
36%
Genetics
33%
Citric Acid Cycle
29%
Glutamine
29%
Mouse
27%
Homeostasis
24%
Mouse Model
23%
DNA Damage
22%
Bile Acid
21%
P53
20%
Tumor Progression
19%
Cancer Cell
19%
Tumor Suppressor Protein
18%
Eicosanoid Receptor
18%
Glucose Oxidation
17%
Gene Mutation
16%
Tumor Necrosis Factor
15%
Stem Cell
15%
Kinase
14%
Phosphotransferase
14%
Ataxia Telangiectasia Mutated
14%
Glucose Metabolism
14%
Enzyme
13%
Receptor Tyrosine Kinase
13%
RNA Interference
12%
Wild Type
12%
ASCL1
12%
T Cell
11%
Overall Survival
11%
Anaplerosis
11%
Cell Cycle
11%
N-Terminus
10%
Transcription Factors
10%
Amino Acids
10%
Liquid
10%
Bioenergy
10%
Cytoskeleton
10%
Alpha Oxidation
9%
Gamma Radiation
9%
Farnesoid X Receptor
9%
Carcinogenesis
9%
Bile Acid Synthesis
8%
Small Intestine
8%
Immunocompetent Cell
8%
Crystal Structure
8%
RNA
8%
Surface Property
8%
Homologous Recombination
8%
Oncogene
7%
Receptor Gene
7%
Confocal Microscopy
7%
Krebs Cycle
7%
Perfusion
7%
SOX2
7%
DNA Modification
7%
Poly ADP Ribose Polymerase
7%
Gallbladder Motility
7%
Telomere
7%
P300 Coactivator Associated Factor
7%
Cellular Differentiation
7%
Embryonic Stem Cell
7%
Muscle Regeneration
7%
Glutamate Dehydrogenase
7%
Caspase 7
7%
Cytokine
7%
Anabolism
7%
Cytochrome
7%
IDH2
7%
IDH1
7%
Beta-Galactosidase
7%
Estradiol
7%
Liver Receptor Homolog-1
7%
Radiosensitivity
7%
Apoptosome
7%
Clusterin
7%
Tyrosine
7%
IMP Dehydrogenase
7%
RNA-induced Silencing Complex
7%
Heterozygosity
7%
Germline Mutation
7%
Platelet Derived Growth Factor Receptor Alpha
7%
Linear Energy Transfer
7%
Pentose Phosphate Pathway
7%
Lamin
7%
Aptamer
7%
Recombination Repair
7%
Ink4
7%
Phosphofructokinase
7%
Macrolide
7%
Akt Signaling
7%
Cluster Analysis
7%
Caspase-9
7%
X Ray
7%
Isochromosome
7%
Nonsense Mutation
7%
Pregnane X Receptor
7%
Synapsin I
7%
Spermatozoon Maturation
7%
Keyphrases
Glioblastoma
73%
Glioma
50%
2-Hydroxyglutarate (2-HG)
41%
Tumor
32%
Brain Tumor
23%
Glioblastoma multiforme
21%
Isocitrate Dehydrogenase 1 (IDH1)
20%
Overall Survival
19%
Glioma Patients
18%
Astrocytes
16%
Neurotensin
14%
MR Spectroscopy
14%
13C-acetate
14%
Lipids
14%
Glioblastoma Therapy
14%
Whole Brain Radiation Therapy
14%
Human Brain Tumor
14%
Ink4a
14%
Adult Patients
14%
Primary Central Nervous System Lymphoma (PCNSL)
14%
Temozolomide
14%
Hazard Ratio
14%
Lactate
13%
Glutamine
13%
Preganglionic
12%
EGFRvIII
12%
Normal Brain
11%
Aberrations
10%
Poor Prognosis
9%
Platelet-derived Growth Factor Receptor (PDGFR)
9%
Axon Terminal
9%
Stellate Ganglion
9%
Magnetic Resonance Spectroscopy
9%
Human Glioblastoma
9%
Glycine
9%
Metabolic
9%
Receptor Tyrosine Kinase
9%
Isocitrate Dehydrogenase mutation
9%
Bevacizumab
9%
Gliomagenesis
9%
Recurrent Glioblastoma
9%
Astrocytoma
9%
Spectral Fitting
8%
Progression-free Survival
8%
Treatment Outcome
8%
Metabolism
8%
Tumor Cells
8%
Epidermal Growth Factor Receptor
8%
Patient Management
8%
Receptor-interacting Protein Kinase 1 (RIPK1)
8%
Phosphorylation
8%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
7%
Glutamate
7%
IDH-mutant Glioma
7%
Genetic Modification
7%
1H-MRS
7%
Imaging Biomarkers
7%
Point-resolved Spectroscopy (PRESS)
7%
Molecular Diversity
7%
Glucose Oxidation
7%
Tyrosine Kinase Inhibitor
7%
Adult Gliomas
7%
PTEN Tumor Suppressor
7%
Skeletal muscle Regeneration
7%
Clinical Utility
7%
13C Enrichment
7%
VB-111
7%
In Vivo Detection
7%
Fitting Strategy
7%
Tertiary Care Hospital
7%
EGF Receptor Inhibitors
7%
Recurrent Glioblastoma multiforme
7%
RAF1 Fusion
7%
Phase I Study
7%
Triple Refocusing
7%
Metabolic Fate
7%
Nuclear factor-κB
7%
Neutrophilia
7%
Meningioma
7%
Alveolar Rhabdomyosarcoma
7%
Arterial Spin Labeling
7%
Glutamine Anaplerosis
7%
Brain Cells
7%
Tapered Channel
7%
BCNU Wafer
7%
Paraxial Mesoderm
7%
Mutation Status
7%
In Vivo MRS
7%
Backward Walking
7%
Brain Tumor Patients
7%
Primary B Cells
7%
Pregnant Women
7%
Brain Metastases
7%
Nervous System Diseases
7%
Prospective Longitudinal Study
7%
Endobiotics
7%
Worse Prognosis
7%
Tetracycline
7%
Socioeconomic Status
7%
Trebananib
7%